Vmn2r18 inhibitors pertain to a specialized class of chemical compounds that target the Vmn2r18 receptor, which is a part of a larger family of receptors known as vomeronasal type-2 receptors (V2Rs). These receptors are typically found in the vomeronasal organ (VNO), an olfactory structure that is present in many vertebrates, and are implicated in the detection of pheromones, chemical signals that carry information between individuals of the same species. The Vmn2r18 receptor, in particular, is a G protein-coupled receptor (GPCR), which is a common target for various molecular inhibitors due to the pivotal role GPCRs play in cellular signal transduction. The inhibitors of Vmn2r18 are designed to bind selectively to this receptor, affecting its ability to interact with its natural ligands, thereby altering the receptor's normal function.
Chemically, Vmn2r18 inhibitors can be diverse, but they are united in their function to affect the signaling pathways that are mediated by the Vmn2r18 receptor. Their molecular structures are often complex, designed to fit into the specific binding sites of the Vmn2r18 receptor with high affinity. The design of these inhibitors is a sophisticated process, involving a deep understanding of the molecular structure and function of the receptor, as well as the types of ligands that normally bind to it. Through various types of interactions, such as hydrogen bonding, hydrophobic effects, and Van der Waals forces, these inhibitors can effectively prevent the receptor from being activated or inhibit its activity. As such, they are of interest within the field of biochemistry and molecular biology, where the focus is on dissecting and understanding the intricate mechanisms of cellular signaling and the modulation of receptor activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
An inhibitor of Gi/o protein coupling. Vmn2r18 is likely to interact with Gi/o proteins to modulate intracellular signaling. Pertussis toxin ADP-ribosylates Gi/o proteins, preventing their interaction with GPCRs, potentially downregulating Vmn2r18 signaling pathways. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
A chelator of intracellular calcium ions. Vmn2r18 may induce cellular responses through the elevation of intracellular calcium levels. BAPTA-AM, by buffering Ca2+, can inhibit signaling pathways downstream of Vmn2r18 that are dependent on calcium. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
An inhibitor of nitric oxide synthase. Vmn2r18 may engage in signaling pathways involving nitric oxide as a secondary messenger. Inhibition of nitric oxide production by L-NAME could therefore impede Vmn2r18-dependent signaling processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An ERK pathway inhibitor. If Vmn2r18 signaling involves activation of the MAPK/ERK pathway, PD98059 would inhibit this pathway, leading to reduced Vmn2r18 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor. By inhibiting PI3K, LY294002 prevents the formation of PIP3 and subsequent activation of AKT, potentially affecting Vmn2r18 signaling if it is linked to the PI3K/AKT pathway. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
A protein kinase C (PKC) inhibitor. Vmn2r18 may activate PKC through GPCR-mediated signaling pathways. Go6976 would inhibit PKC, potentially decreasing Vmn2r18 function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor, which can decrease phosphorylation of myosin light chain. If Vmn2r18 signaling affects cytoskeletal dynamics through Rho-associated kinases, Y-27632 could inhibit these effects, thereby decreasing Vmn2r18 activity. | ||||||
NF 449 | 389142-38-5 | sc-203159 | 10 mg | $314.00 | 5 | |
A selective Gs alpha subunit inhibitor. If Vmn2r18 is coupled to a Gs protein to increase cAMP levels, NF449 would inhibit this signaling, leading to lowered Vmn2r18 activity. | ||||||